Ligand validation:6MZ1

NXL: (2S,5R)-1-formyl-5-[(sulfooxy)amino]piperidine-2-carboxamide

NXL is a Ligand Of Interest in 6MZ1 designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6MZ1_NXL_B_301	90%	50%	0.084	0.968	0.68	1.24	-	1	0	0	100%	1
6MZ1_NXL_A_301	86%	52%	0.092	0.961	0.71	1.14	-	1	0	0	100%	0.85
6GTH_NXL_A_301	88%	9%	0.093	0.968	2.32	2.18	4	5	3	0	100%	1
6MZ2_NXL_B_301	86%	73%	0.107	0.975	0.74	0.33	-	-	3	0	100%	1
8B3M_NXL_A_301	68%	8%	0.122	0.933	2.81	1.81	6	6	2	0	100%	1
4HBU_NXL_A_301	100%	51%	0.04	0.993	0.56	1.31	-	1	2	0	100%	1
9BZQ_NXL_A_401	99%	38%	0.059	0.986	1.51	0.93	1	-	0	0	100%	1
4S2I_NXL_B_301	96%	11%	0.06	0.97	2.33	1.82	3	4	0	0	100%	1
4S2J_NXL_D_301	95%	13%	0.063	0.966	1.39	2.57	2	3	2	0	100%	1
8RWP_NXL_A_502	95%	61%	0.062	0.965	0.5	0.98	-	1	0	0	100%	0.61

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.